drugset / Trial / NCT01085838
Erlotinib in Higher Risk Myelodysplastic Syndrome
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study is to evaluate the toxicity and therapeutic efficacy of erlotinib in high-risk myelodysplastic syndrome (MDS) patients (with at least 10% of bone marrow blasts) ineligible for or having failed intensive chemotherapy and ineligible or after failure of treatment with a hypomethylating agent.
Timeline
- Start
- 2010-07
- Primary completion
- 2014-03
- Completion
- 2014-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 100 mg | Oral |
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Erlotinib | Small molecule | 300 mg | Oral |